Browse studies

Find your next paid study

1 recruiting study matching your filters

Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide Combined With Metastasis-Directed Stereotactic Body Radiotherapy for Oligorecurrent Prostate Adenocarcinoma (ANDROMEDA)

This phase II trial compares the use of 225Ac-PSMA-617 to 177Lu-PSMA-617, along with stereotactic body radiotherapy for the treatment of prostate cancer that h…

Oligometastatic Prostate AdenocarcinomaRecurrent Prostate Adenocarcinoma

Jonsson Comprehensive Cancer CenterNCT07150715